Papilloma refers to a benign growth caused by the human papillomavirus (HPV), which is also the leading cause of cervical cancer. Every two minutes, a woman dies from cervical cancer, with global cases rising alarmingly. Despite routine HPV vaccinations preventing most cases, a high unmet clinical need for advanced therapies persists. Current treatment options, such as surgery or cryotherapy, are often invasive and limited. However, the growing focus on immunotherapies, targeted treatments, and antiviral drugs is set to drive pipeline development. These advancements aim to provide safer, more effective solutions to combat human papillomavirus-related diseases, addressing this critical global health challenge.
Major companies involved in the papilloma pipeline analysis include Labo'Life, Catalysis SL, Theravectys S.A., and others.
Leading drugs currently in the pipeline include 2LPAPI, PRGN-2012, Lenti-HPV-07, and others.
The rising prevalence of HPV-related disease, advancements in immunotherapy, and increased research focus on targeted and antiviral treatments are expected to positively influence the papilloma pipeline landscape.
The Papilloma Pipeline Insight Report by Expert Market Research gives comprehensive insights into papilloma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for papilloma. The papilloma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The papilloma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with papilloma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to papilloma.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Papilloma refers to growths caused by the human papillomavirus (HPV), which infects epithelial cells, leading to benign tumors. HPV is transmitted through skin-to-skin contact, and while most infections resolve on their own, some can lead to cervical, anal, or throat cancers. The drug pipeline is focused on developing antivirals, immune-based therapies, and vaccines to prevent and treat HPV-related diseases.
Papilloma treatments include cryotherapy, surgical removal, and laser therapy, which target visible warts. For cervical papilloma, HPV vaccines like Gardasil offer prevention. Antiviral treatments and immune therapies are also being explored to target the virus and reduce recurrence, offering more comprehensive management for patients. In January 2025, the U.S. Food and Drug Administration granted orphan drug designation to pembrolizumab, a PD-1 checkpoint inhibitor, for treating recurrent respiratory papillomatosis.
The papilloma pipeline addresses the increasing global burden of human papillomavirus-related diseases. In Eastern Europe and Southeast Asia, the prevalence of cervical HPV among women has reached 14%. In India, over 80% of sexually active women are likely to acquire genital HPV by age 50. In the United States, from 2017 to 2021, approximately 47,984 new HPV-associated cancer cases were reported annually. These statistics highlight the urgent need for innovative therapies.
This section of the report covers the analysis of papilloma drug candidates based on several segmentations, including:
By Phase
The pipeline report covers 50+ drug analyses based on phase:
By Drug Class
The papilloma pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The papilloma assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II with 48.21%, covers a major share of the total papilloma clinical trials. It is followed by phase I at 23.21%, phase IV at 14.29%, phase III at 8.93%, and early phase I at 5.36%. This strong focus on mid-stage development highlights significant progress in papilloma research. Advancements across all phases are expected to impact the papilloma market with innovative treatment options positively.
The drug molecule categories covered under the papilloma pipeline analysis include small molecules, monoclonal antibodies, vaccines, and immunotherapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for papilloma. Small molecule inhibitors targeting the human papillomavirus (HPV) E5 oncogene protein are gaining attention in the papilloma pipeline. For instance, TGN-S11 by Toragen, Inc. is under Phase 1 investigation as both a monotherapy and in combination with pembrolizumab. It has demonstrated early signs of antitumor activity and safety, supporting further clinical development for HPV-associated cancers.
The EMR papilloma pipeline report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Papilloma clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging papilloma drugs. It includes product description, trial ID, study type, drug class, administration mode, and papilloma drug candidates' recruitment status.
The Phase 4 study, sponsored by Labo'Life, aims to evaluate the efficacy of 2LPAPI® in clearing genital high-risk HPV (HR-HPV) infections. This placebo-controlled trial includes an estimated 284 participants and spans a 72-month duration. The study began on October 17, 2020, and is expected to be completed by October 30, 2027, with primary results anticipated by March 2027.
Precigen, Inc. is sponsoring a Phase 3 confirmatory study to assess the efficacy and safety of PRGN-2012 for treating recurrent respiratory papillomatosis (RRP) in adults. This single-arm, open-label trial involves about 42 participants with a history of repeated surgical debulking. The study began on July 11, 2024, and is estimated to complete primary evaluation by March 2027, with completion by March 2029.
The clinical trial, sponsored by Theravectys S.A., aims to evaluate the safety, immunogenicity, and preliminary efficacy of Lenti-HPV-07 immunotherapy for HPV-associated cervical and oropharyngeal cancers. The objective of this Phase 1/2a study is to assess whether Lenti-HPV-07 induces an immune response and its safety profile. The study is expected to be completed by December 2026, with around 72 participants enrolled.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Papilloma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for papilloma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into papilloma collaborations, regulatory environments, and potential growth opportunities.
Human Papillomavirus (HPV) Drug Pipeline
Global Human Papillomavirus (HPV) Vaccine Market
Human Papillomavirus-Positive Oropharyngeal Cancer Drug Pipeline
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share